CytomX Therapeutics, Inc. (NASDAQ:CTMX) Sees Significant Decline in Short Interest

CytomX Therapeutics, Inc. (NASDAQ:CTMX) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 7,150,000 shares, a decline of 9.1% from the August 15th total of 7,870,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the short-interest ratio is presently 6.5 days.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock traded down $0.02 during trading on Wednesday, reaching $1.19. 851,194 shares of the company’s stock were exchanged, compared to its average volume of 2,912,922. The company’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.74. CytomX Therapeutics has a 52-week low of $1.04 and a 52-week high of $5.85. The firm has a market cap of $92.72 million, a price-to-earnings ratio of 5.95 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a negative return on equity of 27.44% and a net margin of 9.27%. The business had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.79 million. During the same period last year, the company posted ($0.02) earnings per share. Analysts anticipate that CytomX Therapeutics will post -0.2 EPS for the current year.

Institutional Trading of CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in CytomX Therapeutics in the 1st quarter valued at about $57,000. XTX Topco Ltd boosted its position in CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares during the last quarter. Forefront Analytics LLC boosted its position in CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 40,309 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in CytomX Therapeutics in the 1st quarter valued at about $124,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on CTMX. Piper Sandler raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $2.25 to $3.50 in a research note on Tuesday, May 28th. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, September 13th. Finally, StockNews.com cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.77.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.